NVS stock forecast, quote, news & analysis

Key Takeaways

• Novartis (NVS) closed near $151.12 on October 23, 2026, up roughly 4% over the trailing 30 days as shares recovered from a sharp September decline.
• The stock fell about 10.9% on September 8 after two late-stage trial setbacks in a single week, including a miss for del-desiran acquired through Avidity Biosciences.
• On October 23, late-stage multiple sclerosis data for remibrutinib showed a reduction in flare-ups below the level achieved by a rival drug from Roche Holding, pressuring shares ahead of earnings.
• Novartis reports third-quarter results on October 27, 2026; consensus expectations point to EPS near $2.25 on revenue of roughly $14.5 billion.
• Growth increasingly depends on newer brands such as Kisqali and Scemblix offsetting generic erosion of the blockbuster heart drug Entresto.
• Analyst sentiment is broadly neutral, with a consensus Hold rating and an average price target near $150.
• For deeper insight into this ticker, explore Novartis Price Targets, Earnings, and Forecast pages.
• To discover automated strategies trading this and thousands of other tickers, explore Trending AI Robots.

Current Market Snapshot

Novartis shares have stabilized in the low-to-mid $150s after a volatile stretch. The stock bottomed near $137 in early September following back-to-back pipeline disappointments, then steadily climbed through October to close at $151.12 on October 23, 2026. That recovery, however, paused late in the month when remibrutinib multiple sclerosis data came in below a competing treatment from Roche Holding, triggering a single-session decline of more than 3%. The stock remains well below its early-September peak near $163, reflecting ongoing uncertainty around the pipeline even as the base business shows resilience. Within the broader market, healthcare names have benefited from defensive positioning amid a rotation away from artificial-intelligence momentum trades, though that tailwind has been uneven.

Novartis (NVS) Business Overview and Competitive Position

Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel, focused exclusively on innovative prescription medicines after completing the spin-off of its Sandoz generics and biosimilars business in 2023. Led by CEO Vas Narasimhan, the company operates across four core therapeutic areas: oncology, immunology, cardiovascular/renal/metabolic diseases, and neuroscience. Major products include Entresto, Cosentyx, Kesimpta, Kisqali, Scemblix, Leqvio, and the newly approved remibrutinib, marketed as Rhapsido. The company has set a target of 5% to 6% compound annual sales growth from 2025 through 2030, anchored by newer priority brands and a late-stage pipeline strengthened by acquisitions such as Avidity Biosciences and the announced Excellergy deal. Investors follow Novartis for its diversified portfolio, dividend, and long runway of pipeline catalysts, while weighing the near-term drag from Entresto's loss of U.S. market exclusivity.

Recent Developments Driving NVS

Several verified events have shaped Novartis shares over the past month. In early October, the company announced a licensing agreement with China-based Abogen Biosciences, paying $575 million upfront with up to $7.2 billion in potential milestone payments for an mRNA-encoded T-cell engager targeting autoimmune disease. On the analyst front, ratings have been mixed: Citi and Bank of America maintained Buy ratings, while Berenberg and Barclays held at Hold, Goldman Sachs initiated at Sell, and RBC and UBS remained neutral. On October 23, Novartis reported results from two late-stage studies of its multiple sclerosis pill remibrutinib showing a reduction in flare-ups below that achieved by Roche Holding's rival therapy, contributing to a more than 3% single-day decline. These developments followed a broader narrative in which Entresto's U.S. sales fell roughly 50% year over year amid generic competition, while Kisqali and Scemblix grew 43% and 89% respectively at constant currencies in the second quarter.

Trending AI Robots

Tickeron operates hundreds of AI-powered trading bots that monitor thousands of tickers across a wide range of strategies, timeframes, and performance metrics. Rather than presenting every bot, Tickeron curates only the top-performing and most relevant systems in its Trending AI Robots section, giving traders a focused view of strategies currently generating notable signals. Because each bot differs in its approach — from short-term momentum to longer-horizon swing models — investors can review the selection to see whether any align with their own objectives. Exploring this page offers a practical way to observe how automated, data-driven strategies are responding to current market conditions across the broader equity universe.

2026 Outlook and What Investors Should Watch

Looking ahead, the most immediate catalyst is Novartis' third-quarter earnings report on October 27, 2026, where investors will scrutinize core operating income, margin trends, and any update to full-year guidance. The trajectory of Entresto's generic erosion versus the growth of newer brands remains central to the near-term financial story. On the pipeline side, market participants will continue to assess remibrutinib's multiple sclerosis data and regulatory path, as well as upcoming readouts including the cardiovascular asset pelacarsen. Macroeconomic factors such as currency movements between the U.S. dollar and Swiss franc, healthcare policy developments, and the broader appetite for defensive pharmaceutical exposure will also influence sentiment. As with any pharmaceutical investment, clinical and regulatory outcomes introduce meaningful uncertainty that should be weighed alongside valuation and growth expectations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations